ISSN 1662-4009 (online)

ey0020.10-6 | New Drugs for Children with T2DM | ESPEYB20

10.6. Deterioration of glycemic control in youth-onset type 2 diabetes: What are the early and late predictors?

P Zeitler , L El Ghormli , S Arslanian , S Caprio , E Isganaitis , MK Kelsey , RS Weinstock , NH White , K Drews

Brief summary: In this study of 699 youth 10 to < 18 years old with <2 years duration of type 2 diabetes (T2D) at 15 centers across the USA, baseline HbA1c level, and the change in HbA1c level in the first 6 months are predictors of rapid glycemic deterioration. In addition, subsequent loss of control can be predicted based on both baseline and ongoing clinical characteristics.Comment: The population of individuals with youth-onset T2D is heterog...

ey0020.10-4 | New Drugs for Children with T2DM | ESPEYB20

10.4. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes

SA Arslanian , T Hannon , P Zeitler , LC Chao , C Boucher-Berry , M Barrientos-Perez , E Bismuth , S Dib , JI Cho , D Cox , AWARD-PEDS Investigators Cox

Brief summary: This randomized, double-blind, phase 3 trial of youths with inadequately controlled T2D, dulaglutide treatment was superior to placebo in reducing the glycated hemoglobin level at 26 weeks.Comment: T2D in children and adolescents is an aggressive disease with early onset of complications, leading to significant morbidity and mortality. After three decades with no efficient treatment, there is finally light at the end of the tunnel.<p c...